SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to the successful orbital launch and separation of its BlueBird 6 satellite, marking a significant advancement for its direct-to-device cellular broadband network. The community, dubbed "spacemob," is highly enthusiastic, anticipating substantial long-term growth and a potential short squeeze as the company progresses in connecting the unconnected.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is trending as a new low-float aerospace IPO, sparking intense community discussion around a potential short squeeze. Traders are actively debating perceived price manipulation and the high cost to borrow shares, contrasting fundamental concerns with speculative hopes for significant upward moves. This interest is amplified by broader market attention on the space sector, driving highly volatile trading.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is currently a top trending stock following the announcement of its highest-grade silver discovery ever at its Nevada operations, reigniting significant investor interest. This news, combined with a strong precious metals market, has driven substantial gains and fueled community discussions about a potential short squeeze, even as some voices raise caution regarding the company's current lack of revenue.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently trending as its stock experiences a significant decline, sparking intense community debate despite recent bullish partnerships with Meta and Nvidia for AI infrastructure and power-efficient computing. Many question the steep sell-off, attributing it to a recent Goldman Sachs downgrade and perceived market manipulation, while others view the pullback as a prime buying opportunity for a company fundamental to future AI and robotics.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is trending due to its recently announced AI infrastructure partnership with Anthropic and Fluidstack, securing a 15-year data center lease potentially valued at up to $17.7 billion and backed by Google. This transformative deal has captivated the community, as investors view Hut 8's strategic pivot from primarily Bitcoin mining to a key player in high-performance computing as a significant re-rating event, highlighting the immense demand for AI infrastructure.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is trending amidst sharply divided community sentiment, primarily fueled by the recent launch of its Midnight zero-knowledge sidechain and the upcoming integration of USDC, which are seen as pivotal for network scalability and utility. Despite these key ecosystem advancements, a vocal segment of the community expresses frustration over the asset's sustained underperformance, while dedicated holders view current valuations as strategic accumulation points.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is generating significant buzz as investors eagerly anticipate the imminent FDA decision for its Narsoplimab drug, with the PDUFA date approaching rapidly. The community is highly optimistic for approval, especially given the drug's first-in-class status for an unmet medical need and a recent substantial deal with Novo Nordisk, which many believe sets a higher value floor for the company. Despite recent price volatility and suspected market manipulation by shorts, sentiment remains strong for a transformative approval that could lead to a significant revaluation.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow Jones Industrial Average is drawing significant attention as positive economic data and mounting expectations for Federal Reserve interest rate cuts bolster a strong bullish sentiment. Community discussions highlight an active "Santa Rally" and anticipate the index reaching new all-time highs, driven by broader market participation and a rotation into diverse sectors beyond just technology.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is a focal point of market discussion driven by recent insider share acquisitions by the CEO, combined with a very low float and high cost-to-borrow, igniting short squeeze speculation. While many anticipate a massive rally comparing it to previous volatile "China plays" with often extreme price movements, others express skepticism regarding its high market capitalization and lack of revenue, especially amid reports of a DOJ investigation into its past stock volatility.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is currently trending following Moody's upgrade to investment grade, validating its strong credit metrics and consistent growth in Latin American e-commerce and fintech. The community is actively debating the impact of its bold shipping strategies driving Gross Merchandise Volume, with some frustrated by recent price volatility while others see the stock as a compelling long-term buy given its expanding ecosystem and attractive valuation despite short-term margin investments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kura Oncology (NASDAQ:KURA) Shares Gap Up - Here's Why

Kura Oncology (NASDAQ:KURA) Shares Gap Up - Should You Buy...

Kura Oncology, Inc. $KURA Stock Position Lifted by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 37.6% in the third quarter, according to its most recent 13F filing with the Securities and...

Francis Burrows Sells 23,726 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Francis Burrows sold 23,726 shares of the firm's stock in a transaction on Thursday, December 18th. The shares were sold at an average...

Lightning Round: Don't get involved in any 'year of magical investing' stock: Jim Cramer

'Mad Money' host Jim Cramer weighs in on stocks including: SentinelOne, Kura Oncology, Bitmine Immersion Technology, Ciena, and Credo Technology...

Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the thirteen research firms that are currently covering the firm, Marketbeat.com reports...

EcoR1 Capital LLC Boosts Stock Position in Kura Oncology, Inc. $KURA

EcoR1 Capital LLC increased its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 59.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The...

Kura Oncology, Inc. $KURA Shares Sold by Armistice Capital LLC

Armistice Capital LLC trimmed its holdings in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 5.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC...

Kura Oncology (NASDAQ:KURA) Shares Down 4.6% - What's Next?

Kura Oncology (NASDAQ:KURA) Trading Down 4.6% - Here's What Happened...

Kura Oncology, Inc. $KURA Shares Sold by Walleye Capital LLC

Walleye Capital LLC reduced its holdings in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 17.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange...

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points PR Newswire VANCOUVER, BC, Dec...

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Current Price	$10.79
Prev Close	$11.27
Open	$11.27
Dividend Yield	0.00%
50-Day Moving Average	$10.63
Beta	1.03
Avg. Volume	2.17M
PE Ratio	-4.35

52-Week High	$12.49
52-Week Low	$5.41
Market Capitalization	$980.69M
EPS (Annual)	-$2.02
Price to Book	3.87
Revenue Per Employee	$280,640.63
Enterprise Value/EBITDA	N/A

KURA
Kura Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KURA News

KURAKura Oncology Inc